

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Rezlidhia Prior Authorization Policy

- Rezlidhia™ (olutasidenib capsules – Rigel)

**REVIEW DATE:** 12/14/2022

---

### OVERVIEW

Rezlidhia, an isocitrate dehydrogenase-1 (*IDH1*) inhibitor, is indicated for the treatment of relapsed or refractory **acute myeloid leukemia** with a susceptible *IDH1* mutation as detected by an FDA-approved test in adults.

### Guidelines

The National Comprehensive Cancer Network (NCCN) acute myeloid leukemia guidelines (version 3.2022 – January 13, 2023) recommend Rezlidhia or Tibsovo® (ivosidenib tablets) for patients with relapsed or refractory AML with an *IDH1* mutation.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Rezlidhia. All approvals are provided for the duration noted below.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Rezlidhia is recommended in those who meet the following criteria:

#### FDA-Approved Indication

1. **Acute Myeloid Leukemia.** Approve for 1 year if the patient meets the following (A, B, and C):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) Patient has relapsed or refractory disease; AND
  - C) Patient has isocitrate dehydrogenase-1 (*IDH1*) mutation positive disease as detected by an approved test.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Rezlidhia is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Rezlidhia™ capsules [prescribing information]. San Francisco, CA: Rigel; December 2022.
  2. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 3.2022 – January 13, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 17, 2023.
-

**HISTORY**

Type of Revision	Summary of Changes	Review Date
New Policy	--	12/14/2022
Update	<b>1/17/2023:</b> The guidelines section was updated to reflect updated guideline recommendations that include Rezlidhia.	--